Bio-Rad Laboratories (NYSE:BIO) Given New $440.00 Price Target at Royal Bank Of Canada

Posted by Brenda Bartman on Nov 6th, 2026

Bio-Rad Laboratories (NYSE:BIO – Free Report) had its price target lifted by Royal Bank Of Canada from $390.00 to $440.00 in a report published on Thursday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the medical research company’s stock.

Several other equities analysts have also recently issued reports on BIO. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Citigroup raised their price target on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of Bio-Rad Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wells Fargo & Company upped their price objective on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $366.67.

View Our Latest Report on Bio-Rad Laboratories

Bio-Rad Laboratories Trading Down 2.8%

Shares of NYSE:BIO opened at $369.29 on Thursday. Bio-Rad Laboratories has a 12-month low of $236.73 and a 12-month high of $396.23. The company has a market capitalization of $9.87 billion, a PE ratio of 9.73 and a beta of 1.06. The business has a 50 day moving average of $373.87 and a two-hundred day moving average of $315.17. The company has a current ratio of 3.14, a quick ratio of 2.33 and a debt-to-equity ratio of 0.11.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.23 by $0.42. The business had revenue of $656.40 million for the quarter, compared to analysts’ expectations of $649.94 million. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.64%. The business’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the company earned $2.26 EPS. As a group, analysts forecast that Bio-Rad Laboratories will post 9.71 EPS for the current year.

Hedge Funds Weigh In On Bio-Rad Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC purchased a new stake in shares of Bio-Rad Laboratories during the second quarter worth approximately $27,000. Hollencrest Capital Management acquired a new position in Bio-Rad Laboratories in the 1st quarter valued at $28,000. Root Financial Partners LLC acquired a new position in Bio-Rad Laboratories in the 3rd quarter valued at $34,000. Nykredit A S purchased a new position in Bio-Rad Laboratories in the 2nd quarter valued at $118,000. Finally, Signaturefd LLC lifted its holdings in Bio-Rad Laboratories by 51.7% in the 3rd quarter. Signaturefd LLC now owns 437 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 149 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

Positive Sentiment: Third-quarter EPS was $2.65, above analyst estimates, while revenue of $656.4 million also topped expectations and increased 0.5% year over year. Zacks Q3 earnings report
Positive Sentiment: Royal Bank of Canada raised its price target to $440 from $390 and maintained an “outperform” rating, signaling increased analyst confidence. RBC recommendations
Positive Sentiment: Bio-Rad is targeting the upper half of its 10%–12% non-GAAP operating-margin range for 2026, which could support profitability despite subdued sales growth. 2026 outlook
Neutral Sentiment: The company expanded the oncology assay menu for its QX700 ddPCR systems, potentially broadening its offerings; the report did not quantify the expected financial impact. Oncology assay expansion
Negative Sentiment: Bio-Rad reaffirmed 2026 currency-neutral revenue growth guidance of -3% to 0.5%, indicating a weak near-term sales outlook that may offset the quarterly earnings beat. 2026 revenue guidance

About Bio-Rad Laboratories

(Get Free Report)

Bio-Rad Laboratories, Inc develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control.

The company’s clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications.